LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
– LNZ100 selected as lead candidate – Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours – Rapid onset and long...
Source: marketscreener.com